Recent Trends in Hematology & Oncology

Trials show that nivolumab in combination with brentuximab vedotin induced high antitumor activity for relapsed or refractory primary mediastinal B-cell lymphoma. Explore more hemonc at: http://bit.ly/2xaW3zT